drugset
drugset / Trial / NCT07046182

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

NCT07046182 ↗

Phase 4 Active not recruiting 34 enrolled Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

To observe the efficacy and safety of the CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma.

Timeline

Start
2023-10-21
Primary completion
2028-05-26
Completion
2028-05-26

Drugs

EvaluationDrugModalityDoseRoute
Background Azacitidine Other / unclassified — —
Background CEP Unknown — —
Background dasatinib anhydrous Small molecule — —

Indications

angioimmunoblastic T-cell lymphoma